Lymphoma Clinical Trials in Baltimore

Showing 621-640 of 742 trials

COMPLETEDPhase 1/2< 1 mile

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

NCT00809276

The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.

LymphomaMultiple MyelomaLeukemia+1 more

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins92 participantsStarted May 2009

Baltimore, Maryland, United States • Houston, Texas, United States • Seattle, Washington, United States

COMPLETEDPhase 234 miles

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00087425

RATIONALE: Drugs used in chemotherapy, such as bryostatin 1, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Bryostatin 1 may help rituximab kill more cancer cells by making them more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving bryostatin 1 together with rituximab works in treating patients with B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia that has not responded to previous treatment with rituximab.

LeukemiaLymphoma

National Institute on Aging (NIA)48 participantsStarted Jul 2004

Bethesda, Maryland, United States

COMPLETEDPhase 134 miles

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

NCT00019838

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of fludarabine when given with UCN-01 in treating patients with recurrent or refractory low-grade lymphoma or leukemia.

LeukemiaLymphoma

National Cancer Institute (NCI)Started Jul 1999

Bethesda, Maryland, United States • Bethesda, Maryland, United States

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

Lymphoma Trials in Other Cities

Depsipeptide in Treating Patients With Solid Tumors

Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Other Conditions in Baltimore